Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date

Published:2018-10 Issue: Volume:Volume 9 Page:329-337
ISSN:1179-271X
Container-title:Patient Related Outcome Measures
language:en
Short-container-title:PROM

Author:

Hathaway Lindsey^ORCID,Sen Jeremy Michael^ORCID,Keng Michael

Publisher

Informa UK Limited

Subject

General Medicine

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab;BioDrugs;2024-04-08

2. Targeted Treatment and Immunotherapy in High-risk and Relapsed/ Refractory Pediatric Acute Lymphoblastic Leukemia;Current Pediatric Reviews;2023-05

3. SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-03

4. Need for pneumococcal revaccination after blinatumomab therapy: A case report;Pediatric Blood & Cancer;2023-02

5. Early‐salvage therapy with venetoclax‐based regimens for induction failure and poor early response acute lymphoblastic leukaemia: A retrospective case series of 13 patients;British Journal of Haematology;2022-09-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP